Physician profile
Michael Thompson
NPI 1689820433
$8,623.39
in general payments reported to CMS, 2019-2025
43 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $620 · 2021: $1,264 · 2022: $617 · 2023: $1,682 · 2024: $2,175 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,709 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,709.43 |
| Education | $133.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,184.45 | 2021-2025 | |
| Biogen, INC. | $707.57 | 2019-2025 | Leqembi, Vumerity, Spinraza |
| Ucb, INC. | $573.86 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Pfizer INC. | $549.76 | 2022-2025 | |
| Lundbeck LLC | $475.62 | 2020-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $417.11 | 2021-2025 | Hyqvia, Gammagard |
| Teva Pharmaceuticals USA, INC. | $407.03 | 2020-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $389.43 | 2019-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $380.78 | 2024-2025 | |
| Lilly USA, LLC | $327.25 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Neurocrine Biosciences, INC. | $321.55 | 2020-2024 | Ingrezza |
| Allergan, INC. | $314.10 | 2019-2022 | |
| Amgen INC. | $304.26 | 2020-2025 | Uplizna |
| Eisai INC. | $275.63 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $230.21 | 2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $204.42 | 2023-2025 | Zeposia |
| Astrazeneca Pharmaceuticals Lp | $159.87 | 2021-2025 | Wainua |
| Argenx US, INC. | $156.92 | 2022-2025 | Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $100.46 | 2025 | Crexont |
| Tanabe Pharma America, INC. | $97.12 | 2020-2025 | Radicava |
| Merz Pharmaceuticals, LLC | $86.34 | 2021-2025 | Inbrija, Xeomin |
| Genentech USA, INC. | $83.24 | 2019-2023 | Ocrevus |
| Ipsen Biopharmaceuticals, INC | $76.02 | 2020-2023 | Dysport |
| Ani Pharmaceuticals, INC. | $69.62 | 2025 | Purified Cortrophin Gel |
| Amylyx Pharmaceuticals, INC. | $66.88 | 2024 | Relyvrio |
| Otsuka America Pharmaceutical, INC. | $66.63 | 2023-2024 | Nuedexta, Rexulti |
| Upsher-Smith Laboratories LLC | $64.63 | 2021 | |
| Sk Life Science, INC. | $60.70 | 2024 | Xcopri |
| Neurelis, INC. | $58.90 | 2020-2024 | Valtoco |
| Emd Serono, INC. | $50.99 | 2025 | |
| Csl Behring | $46.62 | 2025 | Privigen, Kcentra |
| Tersera Therapeutics LLC | $38.45 | 2023 | Quzyttir |
| Kyowa Kirin, INC. | $36.20 | 2021-2024 | Nourianz |
| Alnylam Pharmaceuticals INC. | $31.66 | 2025 | Amvuttra |
| Genzyme Corporation | $30.25 | 2023 | |
| Jazz Pharmaceuticals INC. | $26.38 | 2023 | Epidiolex |
| Boston Scientific Corporation | $24.25 | 2022 | |
| Tg Therapeutics, INC. | $23.01 | 2024 | |
| Livanova USA, INC. | $22.96 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Adamas Pharmaceuticals, INC. | $22.15 | 2020 | |
| Acadia Pharmaceuticals INC | $21.82 | 2024 | Nuplazid |
| Merck Sharp & Dohme LLC | $21.45 | 2024 | Welireg |
| E.R. Squibb & Sons, L.L.C. | $16.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.